re.Mind Capital — Full Portfolio
5 tracked investments · listed companies and verified rows first
ANNA Autism Care provides ABA therapy for autistic children using Naturalistic Developmental Behavioral Intervention alongside parent coaching.
Digital HealthHealthtechWellness & FitnessBoston, US
Aimun Malik(Executive Officer, Director, Promoter)
BoardBinoy Bhansali(Director)Sean Doolan(Director)in
Co-investorsGreyMatterVirtue Ventures
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalNoeticOMX VenturesPsyMed VenturesRA Capital+6 more
Active seed-stage healthcare company
Eugene, US
Nicholas Allen(Chief Executive Officer)Phillip Scripa(Chief Financial Officer and Secretary)William Shortt(Chief Operating Officer)Jan Hardorp(Director)
Co-investorsBIP VenturesJLS
Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHouston, US
Sameer Sheth(Founder)inSunil Sheth(Founder)Nick Halper(Chief Operating Officer)inSteve Goetz(Chief Technology Officer)inAnthony Arnold(Director)
BoardJacob Robinson(Co-founder & CEO)in
Co-investorsArboretum VenturesPsyMed VenturesTMC Venture FundXEIA Venture PartnersCapital FactoryDivergent Capital+3 more
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Director)inThomas Oxley(Founder)in
BoardRahul Sharma(Director)Alex Morgan(Director)inMartin Dieck(Director)
Co-investorsARCH Venture PartnersForepont Capital PartnersID8 InvestmentsKaleida CapitalKhosla VenturesBezos Expeditions+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.